Status:
COMPLETED
Radiation Dose in Humans From Orally Administered Tc99m-Heparin
Lead Sponsor:
University of Utah
Conditions:
Eosinophilic Esophagitis
Eligibility:
All Genders
18-70 years
Phase:
EARLY_PHASE1
Brief Summary
This is a research study of a new agent used for evaluation of inflammation in the GI tract. This agent is investigational and thus is being studied to determine appropriate dosing and administration ...
Eligibility Criteria
Inclusion
- 10 patients with diagnosed EoE (greater than 20 eosinophils per HPF) on esophageal biopsy will be included as the diseased population
- 7 controls (subjects without GI symptoms and known GI disease)
Exclusion
- bleeding diathesis or contraindication to esophageal biopsies
- severe sleep apnea
- incarceration
- pregnancy
- inability to lie flat for 2 hours
- history of bleeding disorder
- Use of steroids
- Breast feeding
- Allergy to heparin or history of severe reaction to heparin
- allergy to mucomyst or severe asthma
Key Trial Info
Start Date :
July 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04069429
Start Date
July 1 2016
End Date
October 1 2020
Last Update
May 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84132